Zobrazeno 1 - 10
of 132
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Oliver Van Oekelen, Karthik Nath, Tarek H. Mouhieddine, Tasmin Farzana, Adolfo Aleman, David T. Melnekoff, Yogita Ghodke-Puranik, Gunjan L. Shah, Alexander Lesokhin, Sergio Giralt, Santiago Thibaud, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Joshua Richter, Shambavi Richard, Hearn J. Cho, Ajai Chari, Saad Z. Usmani, Sundar Jagannath, Urvi A. Shah, Sham Mailankody, Samir Parekh
Publikováno v:
Blood. 141:756-765
B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food and Drug Administration–approved
Autor:
Benjamin T. Diamond, Bachisio Ziccheddu, Kylee H. Maclachlan, Justin Taylor, Eileen Mary Boyle, Juan Esteban Arango Ossa, Thomas Jacob Jahn, Maurizio Affer, Tulasigeri M. Totiger, David G Coffey, Namrata Chandhok, Justin M Watts, Luisa Cimmino, Sydney X Lu, Niccolo Bolli, Kelly L Bolton, Heather J. Landau, Jae H. Park, Karuna Ganesh, Andrew McPherson, Mikkael A. Sekeres, Alexander M Lesokhin, David J. Chung, Yanming Zhang, Caleb Ho, Mikhail Roshal, Jeffrey W Tyner, Stephen D Nimer, Elli Papaemmanuil, Saad Z. Usmani, Gareth J Morgan, Ola Landgren, Francesco Maura
Publikováno v:
Blood.
Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the develo
Autor:
Oliver, Van Oekelen, Karthik, Nath, Tarek H, Mouhieddine, Tasmin, Farzana, Adolfo, Aleman, David T, Melnekoff, Yogita, Ghodke-Puranik, Gunjan L, Shah, Alexander M, Lesokhin, Sergio A, Giralt, Santiago, Thibaud, Adriana, Rossi, Cesar, Rodriguez, Larysa, Sanchez, Joshua, Richter, Shambavi, Richard, Hearn Jay, Cho, Ajai, Chari, Saad Z, Usmani, Sundar, Jagannath, Urvi A, Shah, Sham, Mailankody, Samir, Parekh
Publikováno v:
Blood.
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy (CAR T) has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and there are now two FDA-approved BCMA-directed CAR T products. Ho
Autor:
Syed Rizvi, Frank Fan, David Avigan, Jenna D. Goldberg, Farah Hossain, Muhammad Akram, Jeffrey R. Infante, Andrzej Jakubowiak, Tzu-Min Yeh, Deepu Madduri, Adam D. Cohen, Alicia J. Allred, Jesus G. Berdeja, Enrique Zudaire, Sen Hong Zhuang, Parameswaran Hari, Jordan M. Schecter, Nikhil C. Munshi, Marlene J. Carrasco, Abhinav Deol, William Deraedt, Saad Z. Usmani, Thomas Martin, Mounzer Agha, Alexander M. Lesokhin, Dong Geng, Indrajeet Singh, Carolyn C. Jackson, Myo Htut, Elizabeth O'Donnell, Yunsi Olyslager, A. Keith Stewart, Arnob Banerjee, Sundar Jagannath, Xiaoling Wu, Yi Lin
Publikováno v:
Blood. 136:22-25
Background: Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528; LCAR-B38M CAR-T cells) is a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies designed to confer avidity. In the phase
Autor:
Alicia J. Allred, Jesus G. Berdeja, Lynda C. Doward, Jordan M. Schecter, Parameswaran Hari, Katharine S. Gries, Yunsi Olyslager, Sundar Jagannath, Carolyn C. Jackson, John Fastenau, Rebecca Crawford, Ross Morrison, Myo Htut, Saad Z. Usmani, William Deraedt, Farah Hossain, Muhammad Akram, Deepu Madduri, Marlene Carrasco-Alfonso, Jenna D. Goldberg, Arnob Banerjee, Andrzej Jakubowiak, Adam D. Cohen
Publikováno v:
Blood. 136:13-15
Background: Patients (pts) with multiple myeloma (MM) experience health-related quality of life (HRQoL) decrement due to symptoms such as fatigue, pain, and insomnia. Pt perspectives of their disease and treatment expectations can help inform clinica
Autor:
Nizar J. Bahlis, Markus Hansson, Rian Van Rampelbergh, Cyrille Hulin, Michael O'Dwyer, Aurore Perrot, Torben Plesner, Thierry Facon, Maria Krevvata, William Renwick, Katja Weisel, Shaji Kumar, Hartmut Goldschmidt, Supratik Basu, Saad Z. Usmani, Lionel Karlin, Meir Preis, Annemiek Broyl, Clarissa M. Uhlar, Rachel Kobos, Cyrille Touzeau, Christopher P. Venner, Robert Z. Orlowski, Jianping Wang, Jon Ukropec
Publikováno v:
Kumar, S K, Facon, T, Usmani, S Z, Plesner, T, Orlowski, R Z, Touzeau, C, Basu, S, Bahlis, N J, Goldschmidt, H, O'Dwyer, M E, Venner, C P, Weisel, K, Hulin, C, Karlin, L, Preis, M, Broyl, A, Renwick, W, Hansson, M, Krevvata, M, Wang, J, Van Rampelbergh, R, Ukropec, J, Uhlar, C M, Kobos, R & Perrot, A 2020, ' Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) : The Phase 3 Maia Study ', Blood, vol. 136, no. Suppl. 1, pp. 24-26 . https://doi.org/10.1182/blood-2020-134847
Introduction: Daratumumab (DARA) is a human, CD38-targeting, IgG1κ monoclonal antibody approved as monotherapy in relapsed/refractory multiple myeloma (RRMM) and in combination with standard of care for RRMM and NDMM. The addition of DARA to standar
Autor:
Hervé Avet-Loiseau, Anupa Kudva, Steven Sun, Nikki A. Deangelis, Shaji Kumar, Huiling Pei, Nizar J. Bahlis, Andrzej Jakubowiak, Maria Krevvata, Michele Cavo, Thierry Facon, Rian Van Rampelbergh, Jesús F. San-Miguel, Priya Ramaswami, Maria-Victoria Mateos, Gordon Cook, Saad Z. Usmani, Rachel Kobos, Bruno Paiva, Jon Ukropec, Meletios A. Dimopoulos, Cyrille Touzeau, Hang Quach, Ming Qi, Christoph Heuck, Jianping Wang
Publikováno v:
Blood. 136:18-20
Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action, and has been approved across lines of therapy for the treatment of multiple myeloma. The addition of
Autor:
Ola Landgren, Roman Hájek, Jin Seok Kim, Jianqi Zhang, Katja Weisel, Philippe Moreau, Chris Morris, Ning Go, Laura Rosinol Dachs, Saad Z. Usmani, Peter Mollee, Mehmet Turgut
Publikováno v:
Blood. 136:32-34
Introduction: CANDOR is a multicenter, phase 3, randomized study of adult patients with relapsed or refractory multiple myeloma (RRMM) previously treated with 1-3 prior lines of therapy (NCT03158688). 466 patients received carfilzomib, dexamethasone,
Autor:
Manisha Bhutani, Myra M. Robinson, Shebli Atrash, Jordan Robinson, Daniel Slaughter, Kristen Cassetta, Ami Ndiaye, Saad Z. Usmani, Barry Paul, Peter M. Voorhees
Publikováno v:
Blood. 136:11-13
Background: Targeting B-cell maturation antigen (BCMA) with antibody-drug conjugates (ADCs), bispecific antibodies, or chimeric antigen receptor t-cells (CAR-Ts) has proven safe and effective in recent clinical trials, but relapses remain common. As
Autor:
Nikki A. Deangelis, Shaji Kumar, M. Qi, Thierry Facon, Hervé Avet-Loiseau, Steven Sun, Jesús F. San-Miguel, Rachel Kobos, Hang Quach, Maria Krevvata, Christoph Heuck, Saad Z. Usmani, Rian Van Rampelbergh, Michele Cavo, Anupa Kudva, Bruno Paiva, Huiling Pei, Andrzej Jakubowiak, Ming Qi, Maria-Victoria Mateos, Jon Ukropec, Cyrille Touzeau, Jianping Wang, Priya Ramaswami, Gordon Cook, Meletios A. Dimopoulos, Nizar J. Bahlis
Publikováno v:
Blood. 139(4)
In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/mel